Publications by authors named "Roger D Aitchison"
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors.
Hiroyuki Kobayashi S Gail Eckhardt Jennifer A Lockridge Mace L Rothenberg Alan B Sandler Roger D Aitchison
Cancer Chemother Pharmacol
October 2005
Purpose: RPI.4610 (ANGIOZYME) is a chemically stabilized ribozyme targeting vascular endothelial growth factor receptor 1. The purpose of this study was to evaluate the safety and pharmacokinetics of RPI.
View Article and Find Full Text PDF